Imfinzi
E505480
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Imfinzi canonical | 1 |
| durvalumab | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248761 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Imfinzi Context triple: [AstraZeneca, notableProduct, Imfinzi]
-
A.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
B.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Imfinzi Target entity description: Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
A.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
B.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
immune checkpoint inhibitor
ⓘ
pharmaceutical drug ⓘ prescription medicine ⓘ |
| administeredInCombinationWith |
chemotherapy
ⓘ
etoposide ⓘ platinum-based chemotherapy ⓘ |
| approvalBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToRegimenType |
first-line therapy for certain lung cancers
ⓘ
maintenance therapy ⓘ |
| belongsToTherapeuticArea |
immuno-oncology
ⓘ
oncology ⓘ |
| developedBy |
AstraZeneca
NERFINISHED
ⓘ
AstraZeneca plc NERFINISHED ⓘ |
| hasATCClass | L01FF03 ⓘ |
| hasDosageForm | solution for infusion ⓘ |
| hasDrugClass | PD-L1 inhibitor ⓘ |
| hasGenericName | durvalumab NERFINISHED ⓘ |
| hasINN | durvalumab NERFINISHED ⓘ |
| hasMolecularTarget |
B7-H1
NERFINISHED
ⓘ
CD274 NERFINISHED ⓘ |
| indicatedFor |
bladder cancer
ⓘ
extensive-stage small cell lung cancer ⓘ non-small cell lung cancer ⓘ previously treated advanced urothelial carcinoma ⓘ small cell lung cancer ⓘ unresectable stage III non-small cell lung cancer ⓘ urothelial carcinoma ⓘ |
| indicatedSetting |
locally advanced cancer
ⓘ
metastatic cancer ⓘ |
| isBiologic | true ⓘ |
| isPrescriptionOnly | true ⓘ |
| isTypeOf |
IgG1 kappa monoclonal antibody
ⓘ
human monoclonal antibody ⓘ |
| mechanismOfAction |
blocks interaction between PD-L1 and PD-1 receptors
ⓘ
enhances T-cell mediated immune response against tumor cells ⓘ |
| pharmacologicalEffect |
anti-tumor immune activation
ⓘ
immune checkpoint blockade ⓘ |
| regulatoryStatus |
EMA-approved
ⓘ
FDA-approved ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
PD-L1
NERFINISHED
ⓘ
programmed death-ligand 1 ⓘ |
| therapeuticIntent |
delay disease progression
ⓘ
prolong overall survival ⓘ |
| usedFor |
cancer immunotherapy
ⓘ
oncology treatment ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Imfinzi Description of subject: Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
durvalumab